Chemomab Therapeutics (CMMB) EBITDA (2017 - 2025)

Chemomab Therapeutics' EBITDA history runs 9 years deep, the most recent figure standing at $625.7 billion for Q4 2025.

• Quarterly EBITDA rose 65.9% year-over-year to $625.7 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1002.9 billion (up 165.89% YoY) and the FY2025 annual result came in at $40.9 million, up 34.98% from the prior year.
• EBITDA was $625.7 billion for Q4 2025 at Chemomab Therapeutics, up from $1.7 million in the prior quarter.
• Across five years, EBITDA topped out at $625.7 billion in Q4 2025 and bottomed at -$5.1 million in Q1 2022.
• A 5-year average of $55.7 billion and a median of $5.4 million in 2022 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA tumbled 199.53% — and 2024, when it soared 804319.98%.
• Chemomab Therapeutics' EBITDA stood at $31.0 million in 2021, then jumped by 59.57% to $49.5 million in 2022, then fell by 5.19% to $46.9 million in 2023, then surged by 804319.98% to $377.2 billion in 2024, then surged by 65.9% to $625.7 billion in 2025.
• Business Quant data shows CMMB's EBITDA at $625.7 billion in Q4 2025, $1.7 million in Q3 2025, and $377.2 billion in Q4 2024.